The regulation of phosphoinositide hydrolysis by the type 1␣ metabotropic glutamate receptor (mGluR1␣) was investigated in stably transfected baby hamster kidney (BHK) cells. Incubation of the cells with L-glutamate, quisqualate, and 1-aminocyclopentane-1S,3R-dicarboxylic acid resulted in a marked accumulation of 3 H]InsP 1 responses were similar in control and PTXtreated BHK-mGluR1␣ cells. These changes in the concentration-effect curves for mGluR agonists are consistent with a model in which the receptor associates with PTX-sensitive inhibitory (G i/o ) and PTX-insensitive stimulatory (G q/11 ) G proteins that can each influence PIC activity. The present observations are consistent with a dual regulation of mGluR1␣-mediated PIC activity that could be fundamental in controlling the output of phosphoinositide-derived messengers.
SUMMARY
The regulation of phosphoinositide hydrolysis by the type 1␣ metabotropic glutamate receptor (mGluR1␣) was investigated in stably transfected baby hamster kidney (BHK) cells. Incubation of the cells with L-glutamate, quisqualate, and 1-aminocyclopentane-1S,3R-dicarboxylic acid resulted in a marked accumulation of [ 3 H]inositol monophosphate (InsP 1 ) and inositol-1,4,5-trisphosphate [Ins(1,4,5)P 3 ] mass in a time-and concentration-dependent manner. Pretreatment of BHKmGluR1␣ cells with pertussis toxin [ 100 ng/ml, 24 hr] led to a dramatic 12-16-fold increase in the accumulation of [ 3 H]InsP 1 and a 2-fold increase in Ins(1,4,5)P 3 in the absence of added agonist. Although only very low levels (Յ1 M) of L-glutamate could be detected in medium taken from control and PTXtreated cell monolayers, the PTX-elicited effect on basal [ 3 H]InsP 1 was fully reversed by preincubation of cells in the presence of glutamic-pyruvic transaminase and pyruvate, suggesting that an increased sensitivity to endogenous glutamate was responsible for the apparent agonist-independent activation of phosphoinositidase C (PIC) after PTX treatment. Consistent with this hypothesis, in the presence of glutamic-pyruvic transaminase/pyruvate, the maximal [
3 H]InsP 1 response to quisqualate was increased by Ն75%, and the EC 50 shifted leftward by 65-fold [Ϫlog EC 50 values (molar), 7.26 Ϯ 0.23 versus 5.45 Ϯ 0.07; n ϭ 4) in PTX-treated compared with control cells. In contrast, antagonist effects on agonist-stimulated [ 3 H]InsP 1 responses were similar in control and PTXtreated BHK-mGluR1␣ cells. These changes in the concentration-effect curves for mGluR agonists are consistent with a model in which the receptor associates with PTX-sensitive inhibitory (G i/o ) and PTX-insensitive stimulatory (G q/11 ) G proteins that can each influence PIC activity. The present observations are consistent with a dual regulation of mGluR1␣-mediated PIC activity that could be fundamental in controlling the output of phosphoinositide-derived messengers.
The recent cloning of eight subtypes of mGluR has not only opened up new avenues for exploration of the central actions of this excitatory neurotransmitter but also expanded the potential to target drugs against specific receptor-mediated actions (1) (2) (3) . Recently, novel synthetic glutamate analogues have been developed as ligands at different mGluRs, and of particular significance has been the development of competitive antagonists (4 -7) and their use in identifying the involvement and roles of different mGluR subtypes in fundamental mechanisms such as long term potentiation and long term depression (8 -12) .
The mGluRs form a distinct branch of the G protein-coupled receptor superfamily, sharing topological organization but little sequence homology with other G protein-coupled receptors. Sequence homology and pharmacological profiling have allowed three subgroups of mGluRs, termed I, II, and III, to be described (2, 3) . Group II mGluRs (types 2 and 3) and group III MGluRs (types 4, 6, 7 and 8) both couple to G proteins of the G i/o family to inhibit adenylyl cyclase or modulate ion channel activities (2, 3) ; in contrast, group I mGluRs (types 1 and 5) activate PIC with the subsequent generation of the second messengers Ins(1,4,5)P 3 and diacylglycerol (2, 3, (13) (14) (15) (16) (17) . The G protein or proteins responsible for coupling group I mGluRs to PIC have been the subject of some debate. Thus, although the phosphoinositide responses elicited by agonist stimulation of mGluR5 and the mGluR1␤ splice variant seem to be little affected by PTX treatment (14, 15) , the response to mGluR1␣ activation is substantially (18) . It has been concluded from such studies that mGluR1␣ can stimulate phosphoinositide hydrolysis via PTX-sensitive (G i/o ) and -insensitive (G q/11 ) pathways, and it is possible that the distinct pathways may lead to the activation of distinct PIC isozymes.
In the current study, we examined the coupling of recombinant mGluR1␣ expressed in BHK cells using both [ 3 H]InsP 1 and Ins(1,4,5)P 3 mass accumulations as indices of PIC activity. In contrast to previous reports (13, 15, 16) , we do not observe a decrease in agonist-stimulated inositol (poly)phosphate accumulation after PTX pretreatment but rather find a profound increase in the ability of glutamate receptor agonists to increase PIC activity after toxin treatment. These data provide evidence consistent with a dual regulation of PIC by mGluR1␣ via G q/11 and G i/o .
Experimental Procedures
Cell culture. BHK cells stably expressing the T45A clone of the rat type 1␣ mGluR (15, 16) were cultured in Dulbecco's modified Eagle's (Glutamax-1) medium supplemented with 5% dialyzed fetal calf serum, 0.5 mg/ml G418, 50 g/ml gentamicin, and 1 M methotrexate. BHK-mGluR1␤ cells were maintained in a similar culture medium except that methotrexate was omitted (15) . Vector control cells (BHK-570) (15) were cultured without G418 or methotrexate but in the presence of neomycin (0.1 mg/ml). Cells were maintained at 37°in a humidified atmosphere (95% air/5% CO 2 ) and were passaged every 4-5 days.
[ 4 , 5 mM HEPES, and 10 mM D-glucose, pH 7.4, after equilibration with 95% O 2 /5% CO 2 ) at 37°. Where GPT and pyruvate were added to decrease medium glutamate concentrations, these agents were present for Ն15 min before any other manipulations were performed and Ն30 min before agonist challenge. Where the effects of GPT per se were assessed, GPT/pyruvate-and pyruvateonly-treated cells were compared.
Vector or mGluR-expressing BHK cells were incubated with KHB (supplemented with 10 mM LiCl in experiments in which [ 3 H]InsP 1 was to be determined) for 15 min. Additions of mGluR antagonists were made 15 min before agonist challenge. Incubations were continued in the presence of agonist for the times indicated at 37°. Incubations were terminated by rapid aspiration of incubation media followed by the addition of 0.3 ml of ice-cold 0.5 M TCA. TCA was extracted by repeated washing with water-saturated diethylether (four times three volumes). Then, one volume of 60 mM NaHCO 3 and one volume of 30 mM EDTA were added to four volumes of the extracted supernatant, and samples were stored at 0-4 o C until further analysis.
When inositol phospholipid labeling was assessed, cell monolayers were extracted with acidified chloroform/methanol (40:80:1 volume concentrated HCl) immediately after aspiration of TCA. The recovered [ 3 H]inositol phospholipids were deacylated and the glycerophosphoinositol(phosphates) were resolved by ion exchange chromatography, as previously described (19) .
The [ 3 H]InsP 1 fraction was also resolved by ion exchange chromatography on Dowex AG1-X8 formate form columns (200-400 mesh, 1.0-ml bed volume) as previously described (19) . Ins(1,4,5)P 3 mass assays were performed using an Ins(1,4,5)P 3 -binding protein prepared from bovine adrenal cortex as described (19 L-Glutamate assay. L-Glutamate in the cell monolayer incubation medium was determined after the addition of TCA (0.5 M final concentration) and extraction with diethylether as described above. A standard curve for known amounts of L-glutamate (0.1-100 M) was also prepared in a diethylether-extracted-TCA 'buffer-blank' solution. The spectrophotometric assay was performed according to manufacturer's instructions except that assay constituent volumes were adjusted to allow detection of L-glutamate at concentrations Ն0.3 M.
Preparation of anti-mGluR1␣ antiserum. A 20-mer peptide (sequence: PNVTYASVILRDYKQSSSTC) corresponding to the final carboxyl-terminal 20 amino acids (residues 1180-1199; C-for-L substitution at position 1199) of the primary sequence of mGluR1␣ (20) was synthesized and coupled to the carrier protein keyhole limpet hemocyanin using glutaraldehyde. The peptide/keyhole limpet hemocyanin conjugate was purified by gel filtration and antisera against the conjugate raised in New Zealand White rabbits.
Immunoblotting. Membranes were prepared from control and PTX-treated (100 ng/ml, 24 hr) BHK-mGluR1␣ cells. Membrane proteins were resolved on 7.5% SDS-PAGE minigels and transferred onto nitrocellulose membranes. Blots were blocked in 5% nonfat dry milk/phosphate-buffered saline (blocking solution) overnight and then incubated for 2 hr with a 1:4000 dilution of the mGluR1␣ antiserum in the blocking solution. Blots were washed with three changes of phosphate-buffered saline for 30 min and incubated with a horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1:2000 dilution in blocking solution) for 1 hr. After washing (30 min), immunoreactive proteins were detected with enhanced chemiluminescence (ECL; Amersham, Little Chalford, UK).
Materials. PTX, quisqualic acid, GPT (EC 2.6.1.2), and methotrexate were from Sigma Chemical (Poole, UK). L-Glutamate was obtained from BDH (Poole, UK), and the L-glutamate colorimetric assay kit was obtained from Boehringer-Mannheim (Mannheim, Germany). 4C3HPG and 1S,3R-ACPD were purchased from TocrisCookson (Bristol, UK). myo-[2- (Fig. 1A) . In contrast, Ins(1,4,5)P 3 levels increased to a peak at 30 sec and then declined toward a lower, but still elevated, plateau level (Fig. 1B) . (Table 1 ). In contrast, 1S,3R-ACPD failed to increase significantly the steady state concentration of Ins(1,4,5)P 3 above basal levels, even at 1 mM. Effects of PTX. The treatment of BHK-mGluR1␣ cells for 22-24 hr with 1, 10, or 100 ng/ml PTX had dramatic doserelated effects on basal and agonist-stimulated phosphoinositide turnover that were most marked at the highest concentration of PTX used (Fig. 2) The increase in basal phosphoinositide turnover caused by PTX pretreatment was also observed at the level of Ins(1,4,5)P 3 mass, with PTX-pretreated cells with ϳ100% higher levels of this second messenger (Fig. 2B) . L-Glutamate caused significant increases in Ins(1,4,5)P 3 accumulation in both control and PTX-treated cells, although as with [ 3 H]InsP 1 accumulation the relative increase was less than that after toxin treatment.
Agonist
In contrast to the marked basal effects of PTX treatment on BHK-mGluR1␣ cells, toxin treatment had no significant effect on basal [ (Fig. 3) . However, after PTX pretreatment, the Effects of PTX and enzymic removal of L-glutamate on agonist-stimulated phosphoinositide responses. Despite the lack of evidence that PTX may result in a change in L-glutamate "handling" in BHK cells, a number of studies have highlighted the problem of glutamate transport and the expression and signaling in cells transfected with cDNA for mGluRs (22, 23) . Therefore, we examined the effects of incubation of control and PTX-treated BHK-mGluR1␣ cell monolayers with high activities of GPT and pyruvate to remove residual extracellular L-glutamate. Although this manipulation had no effect on basal [
3 H]InsP 1 accumulation in control cells, GPT/pyruvate (but not 5 mM pyruvate alone) caused a substantial decrease in PTX-treated cells, such that in the presence of 3 units/ml GPT plus pyruvate, there was a reduction in [ 3 H]InsP 1 of Ͼ95% (Fig. 4) . These data strongly suggest that the PTX-induced increase in basal [ 3 H]InsP 1 is attributable to receptor activation by endogenous L-glutamate. Considering that no difference was found in L-glutamate concentration in incubation medium from control and PTX-treated BHK-mGluR1␣ cell monolayers, PTX treatment must bring about a radical adaptation by which mGluR1␣ becomes sensitive to low concentrations (Յ1 M) of L-glutamate. The next series of experiments established that this was the case. As shown in Fig. 5 Because no endogenous G protein-coupled receptors could be demonstrated in these cells, the effect of PTX pretreatment on receptor-independent mechanisms of stimulating phosphoinositide turnover was also assessed. The nonselective G protein activator AlF 4 Ϫ stimulated a modest 2-3-fold increase in [ 3 H]InsP 1 accumulation in BHK-mGluR1␣ cells, and this was significantly enhanced by PTX (Table 2) . Similarly, the Ca 2ϩ -ionophore ionomycin stimulated a modest increase in [ 3 H]InsP 1 accumulation, which was also enhanced after PTX treatment, although in this case the effect did not reach statistical significance (Table 2) . mGluR1␣ expression levels in control and PTXtreated BHK cells. Western blotting revealed that PTX pretreatment of BHK-mGluR1␣ cells had no discernible effect on levels of receptor expression (Fig. 6) . Thus, the antimGluR1␣ antiserum identified similar levels of a protein of ϳ150 kDa in both control and PTX-treated BHK cells. In agreement with a previous report (24) , additional immunoreactive material ran toward the top of the gel (Fig. 6) . The identity of this band is unknown, although it has been pro- 
Discussion
In agreement with reports in BHK (15, 16) and other (13, 22) cell types transfected to express mGluR1␣, we have shown that PIC activity is markedly stimulated by the addition of L-glutamate, quisqualate, and, to a lesser extent, 1S,3R-ACPD. Our data, which assess [ , Ins(1,4,5)P 3 mass accumulation is a more dynamic measurement that reflects the relative rates of synthesis and breakdown of this messenger; presumably the reduced ability of 1S,3R-ACPD to stimulate PIC activity via mGluR1␣ is insufficient to result in a detectable Ins(1,4,5)P 3 accumulation, despite an increased flux through this intermediate (25) .
A recent report demonstrated apparent agonist-independent ("constitutive") activity of mGluR1␣ transiently expressed in either LLC-PK1 or HEK 293 cells (21) . In agreement with these data, we have shown here that basal (lanes 1-3) or 3 g (lanes 4 and 5) of membrane protein/ml. ]InsP 1 accumulation is increased (by ϳ50%) in BHKmGluR1␣ cells compared with vector-transfected cells, and basal phosphoinositide hydrolysis rates are not significantly suppressed by the addition of an enzyme/cosubstrate (GPT/ pyruvate) system for removing extracellular endogenous glutamate or an mGluR antagonist. To further explore the properties of this apparent agonist-independent activity, we choose to selectively manipulate the G protein populations present in BHK cells by using PTX.
The mGluR family members differ in a number of important respects from other members of the G protein-coupled receptor superfamily. Thus, the ligand binding domain (26, 27) and the intracellular domains of the receptor that control the specificity of linkage to G proteins (28, 29) of mGluRs have little in common with other G protein-coupled receptors. Similarly, in contrast to many receptors that link to ␤-isozymes of PIC, the type 1 and 5 mGluRs and their splice variants exhibit varying susceptibilities to inhibition of effector coupling by PTX, suggesting that PIC activation is mediated by both G q/11 -and G i/o -type G proteins (13) (14) (15) (16) (17) (18) . Thus, mGluR1␣-mediated activation of phosphoinositide hydrolysis has been reported to be inhibited by 40 -80% after PTX pretreatment (13, 15, 16) , suggesting that ADP-ribosylation and inactivation of G i/o severely compromise the effector coupling of this splice variant. In the current study, we provided a radically contrasting picture of PTX effects on mGluR1␣-mediated phosphoinositide signaling by presenting evidence demonstrating that there is a marked increase in the ability of mGluR agonists to activate PIC after G i/o inactivation in BHK-mGluR1␣ cells. One possible reason for the disparity between our data and those reported previously (13, 15, 16) may relate to the fact that the earlier studies reported only the effects of agonists as a "fold-over-basal" response, and therefore the major action of PTX on "basal" values may have been overlooked in these studies.
Initial experiments demonstrated that 24-hr pretreatment with 1-100 ng/ml PTX caused a dramatic dose-related increase in [ 3 H]InsP 1 accumulation in the absence of added agonist and at a maximally effective dose of toxin was 12-16-fold greater than in control cells. The facts that similar, very low levels of glutamate (Յ1 M) were observed in incubation medium taken from control and PTX-treated cell monolayers and that exogenous L-glutamate stimulated a further increase in [ 3 H]InsP 1 accumulation initially suggested that PTX was causing a dramatic unmasking of agonist-independent (constitutive) mGluR1␣ activity. Despite such evidence, previous work by other groups (22) , including studies performed in BHK cells (23) , has highlighted the problems that can be associated with systems in which endogenous L-glutamate can contribute to, or account for, receptor activation. Thus, Desai et al. (22) reported that mGluR agonists stimulate a much more dramatic increase in phosphoinositide hydrolysis in AV12 cells transfected to express the human mGluR1␣ in the presence compared with the absence of the cotransfected Na ϩ -dependent glutamate transporter GLAST (30) . Under the assay conditions described by Desai et al. (22) , extracellular L-glutamate concentration was much greater (Ն30 M) if cells were not engineered to express GLAST, leading to tonic receptor activation and desensitization. However, in the current study, much lower levels of L-glutamate (Յ1 M) were detected, suggesting that BHK cells may differ from AV12 cells in their handling of transplasmalemmal glutamate movements or may already possess a glutamate transporter favoring accumulation from the extracellular medium (31) . However, more subtle effects can also occur. Thomsen et al. (23) reported that agents that do not directly interact with mGluR1␣ can, nevertheless, activate phosphoinositide hydrolysis by stimulating heteroexchange mediated by the endogenous glutamate transporter and having the net effect of causing L-glutamate release into the extracellular space sufficient to activate mGluR1␣.
In view of this evidence, we carried out further experiments using the enzyme/cosubstrate addition (GPT ϩ 5 mM pyruvate) used by others to reduce extracellular glutamate concentrations (32) . Although GPT/pyruvate had no effect on [ 3 H]InsP 1 responses in control cells, the elevated basal phosphoinositide hydrolysis in PTX-treated cells was dramatically and fully attenuated under these conditions. In addition, further analysis of the concentration-dependencies of quisqualate-and 1S,3R-ACPD-stimulated [
3 H]InsP 1 accumulation revealed that in the presence of GPT/pyruvate, PTX pretreatment increased the maximal response elicited by the full agonist quisqualate and dramatically reduced the EC 50 value (ϳ65-fold) compared with control cells. The partial agonist 1S,3R-ACPD stimulated a [
3 H]InsP 1 response that was similarly affected with a 2-3-fold increase in the maximal response and a 10-fold leftward shift in EC 50 value. These dramatic changes in the stimulation of phosphoinositide responses seem to occur without any detectable PTXinduced changes in BHK cell mGluR1␣ expression assessed by immunoblotting.
The sensitization and increased responsiveness of the phosphoinositide response to mGluR agonists after PTX treatment fully account for the original observations of dramatic elevations in basal [ 3 H]InsP 1 accumulation. Thus, although a medium L-glutamate concentration of ϳ1 M may have no significant stimulatory effect in control cells, it is sufficient to substantially stimulate phosphoinositide turnover after "sensitization" by PTX treatment. The effect of PTX seems to be much more dramatic in BHK cells expressing the mGluR1␣ splice variant; although the maximal agonist-stimulated response seen in mGluR1␤-expressing BHK cells is increased, a sensitization of the signaling pathway to agonist is not evident. Although further studies are required, these data implicate the carboxyl terminus of mGluR1, in which differential splicing of this receptor occurs (3), as an important domain in the interaction with PTX-sensitive G protein or proteins. Our attempts to examine the effects of PTX on receptor-independent activations of PIC revealed a small enhancement of enzyme activity by AlF 4 Ϫ -mediated G protein activation in PTX-treated cells, which would be consistent with a dual regulation of this effector by G q/11 and G i/o proteins. However, the small responses obtained with AlF 4 Ϫ and the lack of knowledge of the relative activation of the different G proteins by this agent preclude confident interpretation.
Our observations strongly suggest that the ability of activated mGluR1␣ to link to PIC activation (probably via G q/11 ) is negatively modulated by G i/o proteins and that ADP-ribosylation by PTX neutralizes this inhibitory influence (Fig. 8) . Consistent with this model is very recent work from this laboratory (33) that provides evidence that glutamate-stimulated [ 35 S]GTP␥S binding in BHK-mGluR1␣ cell mem-branes involves both PTX-sensitive and -insensitive G proteins. Furthermore, it is interesting to note that the maximum extent of mGluR1␣-mediated G protein activation by glutamate is modest (300 -400 fmol/mg of protein), suggesting that cell-surface mGluR1␣ capable of interacting with G proteins are not dramatically overexpressed in this model cell system (33) . Inhibitory effects of PTX-sensitive G proteins on PIC activity have been suspected for some time (34) , although whether such modulations occur via direct inhibition of PIC, through activation of a distinct signal transduction pathway, or at a noneffector site in the receptor-effector coupling pathway has often been difficult to establish (34 -36) . However, a number of studies have reported direct inhibitory G i/o effects on PIC activity in intact cells (37, 38) and permeabilized cell and membrane preparations (37, 39) . Of particular interest with respect to the current study is the finding of Watkins et al. (40) that G i2␣ expression can negatively modulate agoniststimulated PIC activity. They reported that in mouse F9 tetracarcinoma and rat osteosarcoma cells, down-regulation of G i2␣ by transfection with RNA antisense to this protein or overexpression of a constitutively active Q205L/G i2␣ caused increases and decreases, respectively, in basal phosphoinositide turnover and potentiated or abolished the Ins(1,4,5)P 3 response to thrombin and an ␣ 1 -adrenoceptor agonist (40) . Contrary to initial indications, our data provide no evidence for an enhancement of basal phosphoinositide hydrolysis by PTX per se, but the current data are consistent with those of Watkins et al. (40) with respect to the effect of PTX to enhance agonist-stimulated phosphoinositide responses.
In conclusion ,the present data provide strong evidence that ADP-ribosylation and inactivation of G i/o proteins by PTX result in a dramatic enhancement of mGluR1␣-PIC signaling via G q/11 . It will be important to establish whether this phenomenon occurs for mGluR1␣ in other cell types, whether it depends on receptor expression levels, and whether it is specific to this subtype. Overall, however, these observations are consistent with a dual regulation of receptor-mediated PIC activity that could be fundamental in controlling the output of phosphoinositide-derived messengers. 
